Hotline 24/7: 0909384389

Share links:

Mardil Medical completes treatment of third patient in VenTouch device trial

Ngày 13/04/2020 09:32 | Lượt xem: 1141

Mardil Medical has announced the successful completion of treatment for the third patient in the clinical trial of its improved VenTouch device for type IIIb functional mitral valve regurgitation. A press release reports that the device is a combination therapy which simultaneously treats the distorted valve, the dilated ventricle and the displaced papillary muscles. It adds that VenTouch is a minimally invasive surgical treatment for a condition associated with accelerated heart failure.

According to the press release, VenTouch therapy improves on earlier generations of the technology with the addition of patient-specific inflatable chambers used to correct the displaced mitral valve papillary muscles associated with functional mitral regurgitation. Patients treated with the improved VenTouch device have responded favourably to the therapy, with marked improvements of mitral valve regurgitation, of quality life and of cardiac structure. In all patients, the mitral regurgitation was reduced to only mild or trace amounts.

The latest VenTouch therapy was completed on 23 March at Semmelweis University Heart and Vascular Center in Budapest, Hungary. The Hungarian surgical and cardiology teams were supported by a Mardil team led by Denis Bouchard, George Gellert, and Maurice Sarano.

George Gellert, an imaging specialist and prominent trainer of cardiologists on the latest in echocardiography for structural heart procedures, says: “After application of the VenTouch device, mitral valve regurgitation was markedly reduced. I was very encouraged by the immediate mitral regurgitation reduction and by the significant benefit in both the ventricular function and correction of the valve anatomy in this difficult-to-treat patient population. In my clinical experience with more than 300 transvascular mitral regurgitation interventions, I see some of these patients return with recurring mitral regurgitation following an initially successful therapy. The unmanaged left ventricle dilation causes returning mitral regurgitation in these inoperable patients. Today, these patients have no further therapeutic options. VenTouch can improve leaflet coaptation by correcting the distortion in the valve annulus and left ventricle geometry simultaneously which addresses the root cause of the problem, left ventricle dilation.”

Denis Bouchard (Montreal Heart Institute, Montreal, Canada) says: “Never before has a mitral valve therapy been so entirely planned in the preoperative phase. Before the first skin incision we can determine the position of each inflation chamber entirely based on a personalised 3D heart model of the affected patient. This device is about precision and the sound remodelling of each individual patient’s dilated heart.”

Mardil is also initiating clinical trials to study the VenTouch therapy in patients who also have clinically significant functional tricuspid valve regurgitation and in patients who have had previous transvascular mitral regurgitation interventions that were ineffective, or regurgitation recurred.

Aaron Hjelle, COO of Mardil Medical, says: “This work is the culmination of years of research and clinical activity. It is gratifying to see the impact that the VenTouch therapy is having on these patients, and exciting to consider the impact it may have on the broader clinical population. Mardil is continuing to develop compelling therapies for patients with cardiac valve disease.  Clinical trials for a therapy to treat tricuspid valve regurgitation will begin this year.”

Source CardiovascularNews

Duc Tin Clinic

Tin tức liên quan

Vesteck completes first-in-human use of several Suture-Tight devices

Age is just a number: Individual patient data meta-analysis probes safety of CEA in the elderly

Artificial intelligence can predict risk of complications after endovascular aneurysm repair

Bluegrass Vascular announces Journal of Vascular Surgery paper reporting use of Surfacer system

Vascular access creation: EndoAVF keeps future options open, but is not a replacement for surgical fistulas

SUPPORT CONSULTANT

CUSTOMER REVIEWS

• I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

  I sincerely thank you !. Tel: 0938303275

• Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

  Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

• As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

• The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

• I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search

News

Customer support